Q4 2025 · 13F-HR
Davern Capital Partners, LPholdings as filed
Filed 2026-02-13 · accession 0000905148-26-000704
$309.3M
Reported value
14
Positions
2025-12-31
Period end
The Brief · Davern Capital Partners, LP · Q4 2025
AI · grounded in 13F
Davern Capital Partners, LP established a new position in PFE valued at $50.85M. The fund also initiated new stakes in REGN for $40.46M and BNTX for $35.34M. Additional new positions include RPRX at $32.48M and ARGX at $30.01M. Total assets under management stand at $309.30M across 14 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 717081103 | PFE | PFIZER INC | $50.9M | 16.4% | 2,042,242 | Common | NONE |
| 75886F107 | REGN | REGENERON PHARMACEUTICALS | $40.5M | 13.1% | 52,420 | Common | NONE |
| 09075V102 | BNTX | BIONTECH SE | $35.3M | 11.4% | 371,216 | Common | NONE |
| G7709Q104 | RPRX | ROYALTY PHARMA PLC | $32.5M | 10.5% | 840,650 | Common | NONE |
| 04016X101 | ARGX | ARGENX SE | $30.0M | 9.70% | 35,685 | Common | NONE |
| 52490G102 | LEGN | LEGEND BIOTECH CORP | $23.0M | 7.43% | 1,056,668 | Common | NONE |
| G76279101 | ROIV | ROIVANT SCIENCES LTD | $22.3M | 7.21% | 1,028,298 | Common | NONE |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $18.9M | 6.10% | 238,477 | Common | NONE |
| 632307104 | NTRA | NATERA INC | $18.0M | 5.83% | 78,650 | Common | NONE |
| 532457108 | LLY | ELI LILLY & CO | $8.9M | 2.89% | 8,307 | Common | NONE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $8.1M | 2.63% | 261,615 | Common | NONE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $7.6M | 2.47% | 210,648 | Common | NONE |
| 156944100 | CGON | CG ONCOLOGY INC | $6.7M | 2.17% | 162,005 | Common | NONE |
| 00370M103 | ABVX | ABIVAX SA | $6.5M | 2.11% | 48,502 | Common | NONE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.